Browse by category

Results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses of retatrutide, revealed retatrutide lowered weight by up to an average of 28.7% (71.2 lbs) and reduced pain by up to an average of 4.5 points (75.8%) using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score. Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecul

The first patient has been treated in Nitinotes’ US Investigational Device Exemption (IDE) EASE Clinical Trial evaluating the EndoZip Automated Suturing System for endoscopic sleeve gastroplasty (ESG). The procedure was performed at Lenox Hill Hospital | Northwell Health in New York, NY, the trial's first activated US site. The EASE Clinical Trial is a prospective, multi-centre, randomised, two-arm, blinded pivotal study designed to evaluate the safety and effectiveness of th

Corbus Pharmaceuticals has completed the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study (CANYON-1), with completion expected in the summer of 2026. CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (CB1). This is a recognized mechanism of action for weight loss, but the first generation of experimental drugs in this cla

Transoral outlet reduction (TORe) and anastomotic reduction techniques are gaining momentum as minimally invasive alternatives to surgical revision for managing post-surgical complications such as weight regain and dumping syndrome.(1) BARS® — a novel endoscopic platform developed by Ovesco Endoscopy AG — is among the emerging technologies in this field. As clinical experience with BARS® grows, early data on weight regain management and targeted treatment approaches for enlar

A systematic review and meta-analysis that evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity, has found that the drugs probably have little or no effect on risk for thyroid, pancreatic, breast, or kidney cancer and may have little or no effect on other obesity-related cancers. However, the researchers from Harvard Medical School stated the certainty

Researchers from the Keck School of Medicine (University of Southern California) have found that teenagers with higher blood levels of per- and polyfluoroalkyl substances (PFAS) measured before metabolic bariatric surgery (MBS) had smaller improvements in blood sugar over five years, including fasting glucose and haemoglobin A1c (HbA1c), which measures average blood sugar levels over the past 60–90 days. The results, suggest that PFAS exposure may help explain why metabolic o